Becton Dickinson and Co (NYSE:BDX) Shares Sold by Covington Capital Management

Covington Capital Management decreased its holdings in Becton Dickinson and Co (NYSE:BDX) by 1.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,129 shares of the medical instruments supplier’s stock after selling 150 shares during the quarter. Covington Capital Management’s holdings in Becton Dickinson and were worth $3,574,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. TRUE Private Wealth Advisors acquired a new stake in shares of Becton Dickinson and in the 2nd quarter worth $25,000. Allworth Financial LP boosted its position in shares of Becton Dickinson and by 386.4% in the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 85 shares in the last quarter. Northwest Investment Counselors LLC acquired a new stake in shares of Becton Dickinson and in the 3rd quarter worth $27,000. Lipe & Dalton acquired a new stake in shares of Becton Dickinson and in the 2nd quarter worth $28,000. Finally, Liberty Wealth Management LLC boosted its position in shares of Becton Dickinson and by 293.1% in the 3rd quarter. Liberty Wealth Management LLC now owns 114 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 85 shares in the last quarter. 84.65% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently weighed in on the company. KeyCorp lowered their price objective on Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. Wells Fargo & Co lifted their price target on Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Piper Jaffray Companies lowered their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $266.00.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,532 shares of Becton Dickinson and stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the completion of the transaction, the chief executive officer now owns 218,671 shares in the company, valued at approximately $56,937,554.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Charles R. Bodner sold 1,514 shares of Becton Dickinson and stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $260.08, for a total value of $393,761.12. Following the transaction, the senior vice president now owns 5,180 shares of the company’s stock, valued at approximately $1,347,214.40. The disclosure for this sale can be found here. Insiders have sold a total of 22,345 shares of company stock valued at $5,847,029 in the last quarter. Company insiders own 0.12% of the company’s stock.

Shares of BDX opened at $260.40 on Thursday. The stock has a 50-day moving average of $250.98 and a two-hundred day moving average of $248.19. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $264.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.73 and a current ratio of 1.19. The stock has a market cap of $68.53 billion, a P/E ratio of 22.29, a P/E/G ratio of 1.78 and a beta of 1.09.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.30 by $0.01. The business had revenue of $4.58 billion during the quarter, compared to analyst estimates of $4.57 billion. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The company’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $2.93 EPS. Analysts predict that Becton Dickinson and Co will post 12.57 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 9th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.21%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. Becton Dickinson and’s dividend payout ratio (DPR) is presently 26.37%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: What is a CD ladder?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.